期刊
BIOMARKERS IN MEDICINE
卷 4, 期 1, 页码 91-98出版社
FUTURE MEDICINE LTD
DOI: 10.2217/BMM.09.80
关键词
Alzheimer's disease; amyloid; biomarkers; cerebrospinal fluid; clinical trials; plasma; tau
资金
- Royal Swedish Academy of Sciences
- Swedish Research Council
- Alzheimer's Association
- NIH [U01-AG024904]
This article summarizes how biochemical markers may aid in the development of novel treatments that interfere with fundamental pathogenic processes in Alzheimer's disease. Details are given on the potential use of biomarkers in Alzheimer's disease clinical trials as additional inclusion criteria to enrich study populations with participants who really suffer from the disease, as a means to stratify study participants into meaningful subgroups that may benefit differently from the treatment, and as tools to detect desired biochemical effects and undesired side effects of the drug.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据